Skip to content
A Test for Data-Driven Drug Development episode artwork

Jun 10, 2021 41 min

A Test for Data-Driven Drug Development

from The Bio Report Hosted by Levine Media Group

Sumitomo Dainippon Pharma’s $3 billion strategic transaction with Roivant Sciences that gave rise to Sumitovant, represents an effort by the Japanese drug company to make the drug development process faster and more efficient. A critical piece of this effort is steps the company has taken to harness information technology to capitalize on existing knowledge to inform decision making. We spoke to Bill McMahon, chief algorithmic analytics officer of Sumitovant, about the approach Sumitovant is taking, the way uses information technology to improve the drug development process, and how the subsidiary may be influencing the way its parent company operates.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

A Test for Data-Driven Drug Development

0:00 41:54

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 41 minutes long.

When was this The Bio Report episode published?

This episode was published on June 10, 2021.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.